Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Hasbani Issued a Decision on the Regulation of Surgical Operations in Specialized Hospitals and Reminded Beauty Centers of the Legal Deadline Given until August to Settle their Situation

 
Deputy Prime Minister Health Minister Ghassan Hasbani held a press conference in his office at the Ministry of Public Health, Bir Hassan during which he tackled the organizational frames of beauty Centers and specialized hospitals.
He started by saying: “After the repetitive complaints received by the Ministry of Public Health on accidents and infringements occurring in the sector of Aesthetic Medicine, and as a result of what happened yesterday after the liposuction operation in a specialized hospital, we realized that it is our duty to inform you about the approach of the Ministry to the regulation of aesthetic sector and the actions taken and that being completed through regulatory actions."
 
Beauty Centers

He added: "The Ministry of Public Health followed up the work of the Parliamentary Health Commission for the regulation of Medical Beauty Centers licenses that resulted in the issuance of decision No. 30 of 10 February 2017, which was published in The Official gazette on February 16, 2017.  The Definition of Aesthetic Medicine, its centers and the medical work they are authorized to carry out are regulated by Law which has determined the medical specializations that have the right to hold a permission to practice the profession of Aesthetic medicine. According to the law, the existing Beauty Centers are given a 6 month period to regularize their legal situation as of the date of the publication of this law, i.e. 16 August 2017, under penalty of closing these centers by a decision of Health Minister.

Specialized Hospitals

Health Minister added that he has issued a regulatory decision for specialized hospitals related to the regulation of surgeries which stipulates the following:
  1. Surgeries that may cause complications that require intensive care like liposuction and other surgeries shall not be carried out in places other than specialized hospitals which include an intensive care division which holds a license form Health Ministry in accordance with due process.
  2. The doctor should explain to the patient the risks of the surgery, including the plastic surgery, and ask the patient to sign the Patient Right Form and the informed consent. 
Hasbani stressed that this decision will be immediately communicated to all concerned parties.

Death Case

Hasbani talked also about the recent tragic death of the woman who underwent a liposuction opertaion in a specialized hospital and said: “the Public Prosecution and the Syndicate of Physicians have launched investigations and the Ministry of Public Health has started to investigate and complete the files. The Committee of investigations will meet in the Ministry in order to consider the details of this case and provide consultancies to the Syndicate and Justice where needed.
    ...
    6
    ...
ATC Name B/G Ingredients Dosage Form Price
C09CA03 ARBITEN 80 G Valsartan - 80mg 80mg Tablet 387,027 L.L
C09CA03 ANGINET G Valsartan - 160mg 160mg Tablet, film coated 544,256 L.L
C09CA03 ARBITEN 160 G Valsartan - 160mg 160mg Tablet 544,256 L.L
C09CA04 APROVEL B Irbesartan - 150mg 150mg Tablet, film coated 651,764 L.L
C09CA04 APROVEL B Irbesartan - 150mg 150mg Tablet, film coated 651,764 L.L
C09CA04 ANDARAN G Irbesartan - 150mg 150mg Tablet, film coated 940,435 L.L
C09CA04 APROVEL B Irbesartan - 300mg 300mg Tablet, film coated 651,764 L.L
C09CA04 APROVEL B Irbesartan - 300mg 300mg Tablet, film coated 651,764 L.L
C09CA04 ANDARAN G Irbesartan - 300mg 300mg Tablet, film coated 940,435 L.L
C09CA06 ATACAND B Candesartan cilexetil - 8mg 8mg Tablet 526,786 L.L
C09CA06 ANDESART 8 G Candesartan cilexetil - 8mg 8mg Tablet 498,566 L.L
C09CA06 ARKANDA 8 G Candesartan cilexetil - 8mg 8mg Tablet 478,664 L.L
C09CA06 ATACAND B Candesartan cilexetil - 16mg 16mg Tablet 705,517 L.L
C09CA06 ANDESART 16 G Candesartan cilexetil - 16mg 16mg Tablet 665,202 L.L
C09CA06 ARKANDA 16 G Candesartan cilexetil - 16mg 16mg Tablet 639,925 L.L
C09CA07 ARBIVASTEL G Telmisartan - 80mg 80mg Tablet 667,890 L.L
C09DA03 ARBITEN PLUS G Valsartan - 160mg, Hydrochlorothiazide - 12.5mg Tablet 544,256 L.L
C09DA03 ARBITEN PLUS G Valsartan - 160mg, Hydrochlorothiazide - 25mg Tablet 579,196 L.L
C09DA04 ANDARAN PLUS G Irbesartan - 150mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 598,051 L.L
C09DA04 ANDARAN PLUS G Irbesartan - 300mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 598,051 L.L
C09DA04 ANDARAN PLUS G Irbesartan - 300mg, Hydrochlorothiazide - 25mg Tablet, film coated 940,435 L.L
C09DA06 ATACAND PLUS B Candesartan cilexetil - 16mg, Hydrochlorothiazide - 12.5mg Tablet 705,517 L.L
C09DA06 ARKANDA PLUS 16/12.5 G Candesartan cilexetil - 16mg, Hydrochlorothiazide - 12.5mg 32mg Tablet 642,485 L.L
C09DB01 AMLODIPINE/VALSARTAN ARROW G Amlodipine (besylate) - 5mg, Valsartan - 160mg Tablet, coated 923,220 L.L
C09DB01 ARBITEN AM 5/160 G Amlodipine - 5mg, Valsartan - 160mg Caplet, film coated 857,372 L.L
C09DB01 AMLODIPINE/VALSARTAN ARROW G Amlodipine (besylate) - 10mg, Valsartan - 160mg Tablet, coated 923,220 L.L
C09DB01 ANGIOSAR G Amlodipine besylate - 10mg, Valsartan - 160mg Tablet, film coated 857,372 L.L
C09DB01 ARBITEN AM 10/160 G Amlodipine - 10mg, Valsartan - 160mg Caplet, film coated 857,372 L.L
C09DB01 AMLODIPINE/VALSARTAN ARROW G Amlodipine (besylate) - 5mg, Valsartan - 80mg Tablet, coated 807,649 L.L
C09DX01 ARBITEN AM PLUS G Valsartan - 160mg, Amlodipine - 5mg, Hydrochlorothiazide - 12.5mg Tablet 857,372 L.L
    ...
    6
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026